Genentech’s TECENTRIQ in Combination With Pemetrexed and Platinum-Based Chemotherapy Reduced the Risk of Disease Worsening or Death

- September 24th, 2018

Genentech, a member of the Roche Group (SIX:RO,ROG;OTCQX:RHHBY) announced results from the Phase III IMpower132 study of TECENTRIQ (atezolizumab) plus pemetrexed and platinum-based chemotherapy (cisplatin or carboplatin) for the initial (first-line) treatment of people with non-squamous, non-small cell lung cancer (NSCLC). As quoted in the press release: “This is our third Phase III trial in non-squamous … Continued

Genentech, a member of the Roche Group (SIX:RO,ROG;OTCQX:RHHBY) announced results from the Phase III IMpower132 study of TECENTRIQ (atezolizumab) plus pemetrexed and platinum-based chemotherapy (cisplatin or carboplatin) for the initial (first-line) treatment of people with non-squamous, non-small cell lung cancer (NSCLC).

As quoted in the press release:

“This is our third Phase III trial in non-squamous non-small cell lung cancer demonstrating that a TECENTRIQ-based regimen can help reduce the risk of disease progression for people living with this disease,” said Sandra Horning, M.D., chief medical officer and head of Global Product Development. “We will discuss these results with health authorities globally.”

Data will be presented at the International Association for the Study of Lung Cancer (IASLC) 2018 World Conference on Lung Cancer (WCLC) on Monday, September 24 at 2:35 – 2:45 p.m. EDT (Abstract OA05.07 Oral) and featured in the official WCLC press conference at 9:45 – 10:30 a.m. EDT.

Click here to read the full press release.

Should you invest in the 2020 pharmaceutical market?

Read our FREE outlook report!
 

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select None
Select All

Leave a Reply